Publication list and supplementary information

Size: px
Start display at page:

Download "Publication list and supplementary information"

Transcription

1 Publication list and supplementary information Publications... 2 Peer-reviewed original articles...2 Peer-reviewed review articles...5 Book chapters...6 Editorials, letters, and comments...6 Technology assessments and evidence reports...6 Other relevant publications...6 Presentations... 7 Oral presentations...7 Poster presentations...7 Clinical studies... 8 Protocols...8 Clinical investigator...9 Refereeing Journals...10 Funding bodies...10 Teaching Undergraduate teaching...11 Oral examination of undergraduate students...11 Co-Supervision of higher degree students...11 Postgraduate teaching...11 Supervision of postgraduate degree students...12 Further education...12 Grants March

2 Publications h-index: 18 (Web of Knowledge) 21 (Google scholar) Peer-reviewed original articles 1. Trelle S *, Reichenbach S *, Wandel S, Tschannen B, Hildebrand P, Dieppe P, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: a network meta-analysis. BMJ 2011; 342: c7086. Impact factor: ; Journal ranking: 5/132 (0.96) in Medicine, General & Internal Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: c4675. Impact factor: ; Journal ranking: 5/132 (0.96) in Medicine, General & Internal Muller U, Tanzler K, Burger A, Staub L, Tamcan O, Roeder C, Juni P, Trelle S. A pain assessment scale for population-based studies: Development and validation of the Pain Module of the Standard Evaluation Questionnaire. Pain 2008; 136: Impact factor: 5.371; Journal ranking: 1/25 (0.96) in Anesthesiology Scherer M, Trelle S. Opinions on registering trial details: a survey of academic researchers. BMC Health Serv Res 2008; 8: 18. Impact factor: 1.680; Journal ranking: 29/62 (0.53) in Health Care Sciences & Services Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT ). Haematologica 2007; 92: Impact factor: 5.516; Journal ranking: 9/63 (0.86) in Hematology Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ 2007; 334: 354. Impact factor: 9.723; Journal ranking: 7/100 (0.93) in Medicine, General & Internal Trelle S, Staak JO, Jensen M, Engert A, Reiser M. Implementation and evaluation of a central coordination office for clinical trials in a tertiary care hospital. Onkologie 2005; 28: Impact factor: 1.206; Journal ranking: 103/123 (0.18) in Oncology Trelle S. Accuracy of responses from postal surveys about continuing medical education and information behavior: experiences from a survey among German diabetologists. BMC Health Services Research 2002; 2: 15. Not listed in 2001 (Impact factor: 0.083; Journal ranking: 52/53 (0.038) in Health Care Sciences & Services 2002). 9. Trelle S. Information management and reading habits of German diabetologists: a questionnaire survey. Diabetologia 2002; 45: Impact factor: 5.136; Journal ranking: 14/88 (0.84) in Endocrinology & Metabolism Mean M, Righini M, Jaeger K, Beer HJ, Frauchiger B, Osterwalder J, Kucher N, Lammle B, Cornuz J, Angelillo-Scherrer A, Rodondi N, Limacher A, Trelle S, Matter CM, Husmann M, Banyai M, Aschwanden M, Egloff M, Mazzolai L, Hugli O, Bounameaux H, Aujesky D. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis 2013: In press. * Both authors contributed equally March

3 11. Leunig M, Juni P, Werlen S, Limacher A, Nuesch E, Pfirrmann CW, Trelle S, Odermatt A, Hofstetter W, Ganz R, Reichenbach S. Prevalence of Cam and Pincer-Type Deformities on Hip MRI in an Asymptomatic Young Swiss Female Population: A Cross-Sectional Study. Osteoarthritis Cartilage 2013: In press. 12. Barth J, Bermetz L, Heim E, Trelle S, Tonia T. The current prevalence of child sexual abuse worldwide: a systematic review and meta-analysis. Int J Public Health 2013: In press. 13. Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B, Juni P, Windecker S. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308: Impact factor: ; Journal ranking: 3/155 (0.99) in Medicine, General & Internal Rutjes AW, Juni P, da Costa BR, Trelle S, Nuesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med 2012; 157: Impact factor: ; Journal ranking: 4/153 (0.98) in Medicine, General & Internal Siegenthaler A, Mlekusch S, Trelle S, Schliessbach J, Curatolo M, Eichenberger U. Accuracy of ultrasound-guided nerve blocks of the cervical zygapophysial joints. Anesthesiology 2012; 117: Impact factor: ; Journal ranking: 2/28 (0.96) in Anesthesiology Van Den Berg J, Waser S, Trelle S, Diehm N, Baumgartner I. Lesion characteristics of patients with chronic critical limb ischemia that determine choice of treatment modality. J Cardiovasc Surg (Torino) 2012; 53: Impact factor: 1.352; Journal ranking: 84/185 (0.55) in Surgery Munder T, Gerger H, Trelle S, Barth J. Testing the allegiance bias hypothesis: a meta-analysis. Psychother Res 2011; 21: Impact factor: 1.708; Journal ranking: 42/102 (0.60) in Psychology, Clinical Streitberger K, Muller T, Eichenberger U, Trelle S, Curatolo M. Factors determining the success of radiofrequency denervation in lumbar facet joint pain: a prospective study. Eur Spine J 2011; 20: Impact factor: 1.994; Journal ranking: 20/59 (0.68) in Orthopedics Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, Schurch B, Sievert KD, Engeler DS. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol 2010; 58: Impact factor: 7.667; Journal ranking: 2/63 (0.97) in Urology & Nephrology Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, Egger M, Juni P. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010; 341: c3515. Impact factor: ; Journal ranking: 5/132 (0.96) in Medicine, General & Internal Reichenbach S, Juni P, Werlen S, Nuesch E, Pfirrmann CW, Trelle S, Odermatt A, Hofstetter W, Ganz R, Leunig M. Prevalence of cam-type deformity on hip magnetic resonance imaging in young males: A cross-sectional study. Arthritis Care Res (Hoboken) 2010; 62: Impact factor: 4.152; Journal ranking: 8/26 (0.69) in Rheumatology Reichenbach S, Rutjes AW, Nuesch E, Trelle S, Juni P. Joint lavage for osteoarthritis of the knee. Cochrane Database Syst Rev 2010; 5: CD Impact factor: 5.653; Journal ranking: 11/132 (0.92) in Medicine, General & Internal March

4 23. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: Impact factor: ; Journal ranking: 2/132 (0.98) in Medicine, General & Internal Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009: CD Impact factor: 5.653; Journal ranking: 11/132 (0.92) in Medicine, General & Internal Nuesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R, Altman DG, Juni P. The importance of allocation concealment and patient blinding in osteoarthritis trials: a metaepidemiologic study. Arthritis Rheum 2009; 61: Impact factor: 7.332; Journal ranking: 2/26 (0.92) in Rheumatology Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Burgi E, Scherer M, Altman DG, Juni P. The effects of excluding patients from the analysis in randomised controlled trials: metaepidemiological study. BMJ 2009; 339: b3244. Impact factor: ; Journal ranking: 5/132 (0.96) in Medicine, General & Internal Nuesch E, Rutjes AW, Trelle S, Reichenbach S, Juni P. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009: CD Impact factor: 5.653; Journal ranking: 11/132 (0.92) in Medicine, General & Internal Tendal B, Higgins JP, Juni P, Hrobjartsson A, Trelle S, Nuesch E, Wandel S, Jorgensen AW, Gesser K, Ilsoe-Kristensen S, Gotzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. BMJ 2009; 339: b3128. Impact factor: ; Journal ranking: 5/132 (0.96) in Medicine, General & Internal Urwyler N, Trelle S, Theiler L, Juni P, Staub LP, Luyet C, Alberio L, Stricker K, Greif R. Does point of care prothrombin time measurement reduce the transfusion of fresh frozen plasma in patients undergoing major surgery? The POC-OP randomized-controlled trial. Trials 2009; 10: 107. Impact factor: 2.020; Journal ranking: 5/132 (0.49) in Medicine, Research & Experimental Gerber S, Tallon D, Trelle S, Schneider M, Juni P, Egger M. Bibliographic study showed improving methodology of meta-analyses published in leading journals J Clin Epidemiol 2007; 60: Impact factor: 2.565; Journal ranking: 22/100 (0.78) in Public, Environmental & Occupational Health Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluin-Nelemans HC, Martelli M, Milpied NJ, Santini G, Verdonck LF, Vitolo U, Schwarzer G, Engert A. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-hodgkin lymphoma - Results of a comprehensive meta-analysis. Cancer Treat Rev 2007; 33: Impact factor: 4.539; Journal ranking: 31/132 (0.77) in Oncology Juni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, Zullig M, Guetg R, Jorg Hauselmann H, Schwarz H, Theiler R, Ziswiler HR, Dieppe PA, Villiger PM, Egger M. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: A randomized controlled trial. Arthritis Rheum 2007; 56: Impact factor: 7.677; Journal ranking: 1/22 (0.95) in Rheumatology March

5 33. Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, Juni P, Trelle S. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Care Res 2007; 57: Impact factor: 7.677; Journal ranking: 1/22 (0.95) in Rheumatology Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, Dieppe PA, Juni P. Metaanalysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146: Impact factor: ; Journal ranking: 4/100 (0.96) in Medicine, General & Internal Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-hodgkin's lymphoma. Cochrane Database Syst Rev 2007: CD Impact factor: 4.654; Journal ranking: 14/100 (0.86) in Medicine, General & Internal Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: Impact factor: ; Journal ranking: 4/127 (0.976) in Oncology Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: Impact factor: ; Journal ranking: 2/100 (0.98) in Mecinie, General & Internal Wick C, Egger M, Trelle S, Juni P, Fey M. The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry. Ann Oncol 2007; 18: Impact factor: 4.875; Journal ranking: 23/132 (0.83) in Oncology Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: Impact factor: ; Journal ranking: 4/127 (0.97) in Oncology Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; 3: CD Not listed in ISI Journal Citation Reports Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst 2006; 98: Impact factor: ; Journal ranking: 4/127 (0.97) in Oncology Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinkothe T, Stutzer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: Impact factor: ; Journal ranking: 6/123 (0.95) in Oncology Peer-reviewed review articles 1. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 2006; 3: March

6 Book chapters 1. Gengenbacher M, Juni P, Trelle S. Nichtsteroidale Antirheumatika. In: Forster A (ed). Aktuelle Aspekte in der Therapie der rheumatoiden Arthritis. Bremen, Germany: UNI-MED Science; 2007: Editorials, letters, and comments 1. Juni P, Trelle S, Nuesch E, Rutjes AW, Sterchi R, Reichenbach S. Irrungen und Wirrungen bei der Erforschung von Arthrosetherapien. Schweiz Med Forum 2010; 10: Trelle S. Akupunktur bei Kniearthrose (Kommentar). infomed-screen 2006; 10: 66. Technology assessments and evidence reports 1. Trelle S, Shang A, Nartey L, Cassell J, Low N. Rapid review of evidence for the effectiveness of partner notification for sexually transmitted infections including HIV. London, UK: National Institute for Health and Clinical Excellence; Mar 24, Report No.: PHIAC 4.6. Responsibilities: Literature screening, data extraction and quality assessment, data ana lyses and interpretation, drafting of report. 2. IQWiG. Stammzelltransplantation bei den Indikationen Akute lymphatische Leukämie (ALL) und Akute myeloische Leukämie (AML) bei Erwachsenen. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); Jun, Report No.: N05-03-A. Responsibilities: Protocol development, study selection, and quality assessment. 3. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Rockville, MD: Agency for Healthcare Research and Quality; May 23, Report No.: 3. Responsibilities: Responsible for one of four chapters (Key question 4 Factors for selecting patients or predicting responses to treatment: literature search and screening, data extraction and quality assessment, data analyses and interpretation). Other relevant publications 1. Trelle S. Vitamin C und Erkältung. infomed-screen 2008; 12: Trelle S. Screening auf Bauchaortenaneurysma effektiv? infomed-screen 2007; 11: Trelle S. Folgen einer Grippe-Pandemie heute. infomed-screen 2007; 11: Trelle S. Rekombinantes humanes Erythropoietin: Gibt es prädiktive Faktoren für ein Ansprechen? Onkologie Praxis DGHO (Spezial der Hausarzt Praxis) 2006: Trelle S. Prognostische Relevanz von Q-Zacken beim Herzinfarkt. infomed-screen 2006; 10: Trelle S. ACE-Hemmer bei fortgeschrittener Niereninsuffizienz? infomed-screen 2006; 10: Kober T, Skoetz N, Trelle S, Bohlius J, Engert A. Third biannual report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst 2005; 97: E2. 8. Kober T, Bohlius J, Trelle S, Engert A. Second biannual report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst 2005; 97: E1. 9. Trelle S, Higgins G, Kober T, Engert A. Biannual report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst 2004; 96: E2. March

7 Presentations Oral presentations 1. Trelle S, Kjeldstrom M, Reichenbach S, Juni P. Internet-based data management tool for systematic reviews. Oral presentation at: Cochrane Colloquium; Oct 3-7, 2008; Freiburg, Germany. Proceedings of the 16th Cochrane Colloquium 2008: #O Trelle S, Piper M, Bohlius J, Weingart O, Aronson N, Engert A. Predictive factors of response to recombinant human erythropoietin: quality and results of studies identified by a systematic review. Oral presentation at: Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; Nov 4-8, 2006; Leipzig, Germany. Onkologie 2006; 29 (Suppl 3): #V379. Poster presentations 1. Trelle S, Reichenbach S, Sturdy M, Jüni P. Developing a data management software for systematic reviews and meta-analyses. Poster presented at: 15th Cochrane Colloquium; Oct 23-27, 2007; São Paulo, Brazil. Proceedings of the 15th Cochrane Colloquium: #P59 2. Scherer M, Trelle S. Opinions on registering trial details: a survey of academic researchers. Poster presented at: European General Practice Research Network Meeting; May 10-13, 2007; Nijmegen, The Netherlands. 3. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Nickelsen M, Engert A, Borchmann P. Bortezomib is not active in patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study. Poster presented at: 48th Annual Meeting of the American Society of Hematology; Dec 9-12, 2006; Orlando, FL, USA. Blood 2006; 108: # Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Nickelsen M, Engert A, Borchmann P. Bortezomib and dexamethasone for patients with relapsed Hodgkin's lymphoma: a phase II trial. Poster presented at: Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; Nov 4-8, 2006; Leipzig, Germany. Onkologie 2006; 29 (Suppl 3): #P Trelle S, Kober T, Higgins G, Engert A. Building up a disease-specific trials register in hematooncology: experiences from a project of the Cochrane Haematological Malignancies Group (CHMG). Poster presented at: 12th Cochrane Colloquium; Oct 2-6, 2004; Ottawa, Canada. Proceedings of the 12th Cochrane Colloquium 2004: #P Trelle S. Ideas and assumptions of peer review research: a short review. Poster presented at: 4th International Congress on Peer Review in Biomedical Publication; Sep 14-16, 2001; Barcelona, Spain. Abstract book of the 4th International Congress on Peer Review in Biomedical Publication 2001: #40. Only first or last author presentations provided. March

8 Clinical studies Protocols Consulting especially on study design, sample size and other methodological aspects as well as feasibility, logistics, and regulatory requirements of more than 200 clinical study projects (randomized-controlled trials, single-arm phase II studies, diagnostic accuracy studies, cohort, casecontrol, and cross-sectional studies). 1. Trelle S, Bredenfeld H, Dietlein M, Franklin J, Pfistner B, Eich H, Diehl V, Engert A. A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma (PVAG-14 pilot). Protocol for a clinical study; ; Investigator-initiated, single-arm, phase II multicenter trial. 2. Trelle S, Skoetz N, Borchmann P, Lehmacher W, Pogge Von Strandmann E, Hanke T, Engert A. A phase I trial of TGN1412 a humanized agonistic anti-cd28 monoclonal antibody in patients with B-cell chronic lymphocytic leukemia (TGN1412-I-1). Protocol for a clinical study; Not initiated; Investigator-initiated, phase I, multicenter trial. 3. Trelle S, Elter T, Engert A, Wendtner C-M, Borchmann P, Döhner H, Stilgenbauer S, Hallek M. Multicenter phase II trial of fludarabine and cyclophosphamide in combination with alemtuzumab for patients with relapsed chronic lymphocytic leukemia (FC-Cam): CLL-2L protocol of the German CLL-Study Group (GCLLSG) (CLL-2L). Protocol for a clinical study; ; Investigator-initiated, single-arm, phase II, multicenter trial. 4. Eychmuller S, Trelle S, Fliedner M, Aebersold D, Aujesky D, Fey M, Juni P. A structured early palliative care intervention for patients with advanced cancer a randomized controlled trial with a nested qualitative study (SENS). Protocol for a clinical study; Planning; Investigator-initiated, randomized-controlled, multicenter trial. 5. Weber A, Trelle S, Keller D, Carrel T. Comparison of antithrombotic treatments after aortic valve replacement (CATHAR). Protocol for a clinical study; Recruiting; Investigatorinitiated, single-arm, phase II single center trial. 6. Greif R, Urwyler R, Trelle S, Juni P. Intraoperative coagulation monitoring to reduce the total amount of non-erythrocyte blood products: a randomized-controlled trial (POC-OP trial). Protocol for a clinical trial; ; Investigator-initiated, randomized-controlled, single center trial. 7. Borchmann P, Trelle S, Engert A. Randomized phase II trial of two different dose levels of pixantrone (BBR 2778) in patients with relapsed or refractory Hodgkin's lymphoma. Protocol for a clinical trial; Recruiting; Investigator-initiated, single-arm, phase II multicenter trial. 8. Borchmann P, Trelle S, Diehl V, Engert A. A phase II study of bortezomib in combination with dexamethasone in patients wiith relapsed Hodgkin's lymphoma (Bortezomib in HD). Protocol for a clinical study; ; Investigator-initiated, single-arm, phase II multicenter trial. 9. Borchmann P, Trelle S, Kunze S, Eich HT, Müller R-P, Engert A. A phase II study of rituximab plus low-dose radiotherapy in patients with relapsed non-hodgkin's lymphoma (Rituximab + LD-RT). Protocol for a clinical study; ; Investigator-initiated, single-arm, phase II multicenter trial. March

9 Clinical investigator 1. A phase II study of bortezomib in combination with dexamethasone in patients with relapsed Hodgkin's lymphoma ; investigator-initiated multicenter study. 2. PVAG phase I/II dose finding trial in elderly patients (> 60 years) with advanced stages Hodgkin's lymphoma ; investigator-initiated multicenter study. 3. A phase II study of rituximab plus low-dose radiotherapy in patients with relapsed non- Hodgkin's lymphoma ; investigator-initiated multicenter study. 4. Multicenter phase II trial of fludarabine and cyclophosphamide in combination with alemtuzumab for patients with relapsed chronic lymphocytic leukemia (FC-Cam) CLL-2L protocol of the German CLL Study Group (GCLLSG) ; investigator-initiated multicenter study. 5. A phase II evaluation of oral enzastaurin-hcl in patients with relapsed mantle cell lymphoma ; drug approval study. 6. An open-label, international, multicenter, dose-escalating, phase I/II study of HuMax-CD20 in patients with relapsed or refractory follicular lymphoma grade I-II ; drug approval study. 7. A phase I/II, open-label, dose-excalating study of MDX-060 administered weekly for 4 weeks in patients with refractory/relapsed CD30 positive lymphoma ; drug apporval study. 8. A multi-center phase I/Iia study to investigate the tolerability, safety, pharmacokinetic and pharmacodynamic activity of SDX-101 (R-etodolac) in pateints with B-cell chronic lymphocytic leukemia (CLL) ; drug approval study. March

10 Refereeing Journals 1. Arthritis Care & Research (Impact factor: 7.751; Journal ranking: 1/23 in Rheumatology 2006) 2. Arthritis Research & Therapy (Impact factor: 2.965; Journal ranking: 8/22 in Rheumatology 2004) 3. BMJ (Impact factor: ; Journal ranking: 6/155 in Medicine, General & Internal 2011) 4. European Heart Journal (Impact factor: 9.800; Journal ranking: 3/95 in Cardiac & Cardiovascular Systems) 5. European Journal of Haematology (Impact factor: 2.004; Journal ranking: 31/60 in Hematology 2005) 6. International Journal of Epidemiology (Impact factor: 4.045; Journal ranking: 6/99 in Public, Environmental & Occupational Health 2005) 7. Journal of Clinical Oncology (Impact factor: ; Journal ranking: 6/123 in Oncology 2005) 8. PLoS Clinical Trials (Not listed in Journal Citation Report 2006) 9. Scandinavian Journal of Rheumatology (Impact factor: 2.273; Journal ranking: 11/23 in Rheumatology 2006) 10. Swiss Medical Weekly (Impact factor: 1.346; Journal ranking: 42/103 in Medicine, General & Internal 2006) 11. Trials (Not listed in Journal Citation Report 2006) Funding bodies 1. Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research, Germany) 2. Deutsche Forschungsgemeinschaft (German Research Foundation) 3. Schweizerischer Nationalfonds (Swiss National Science Foundation) 4. Werner und Hedy Berger-Jansen Stiftung Impact factor of the first year of refereeing provided. March

11 Teaching Undergraduate teaching 1. Einführung Critical Appraisal. Every Summersemester since University of Bern, Switzerland. Lecture on critical appraisal of clinical studies (4x2 lessons; 4x40 3 rd -year medical students). 2. Module on Biostatistics and Epidemiology. Every Summersemester since Universities of Bern and Freiburg, Switzerland. Biostatistical practical on measures of risk, lecture on planning and reporting randomized-controlled trials, practical on critical appraisal of randomizedcontrolled trials, lecture on systematic reviews and meta-analysis (10 lessons overall; 25 3 rd - year Bachelor of Biomedical Sciences students). 3. Fachpraktikum Gesundheit im Alter. Every Summersemester since University of Bern, Switzerland. Practical on critical appraisal of clinical studies (4x4 lessons; 4x10 3 rd -year medical students). Responsible for organization and coordination of the course. 4. Block Störungen von Kognition, Emotion und Verhalten, Summersemester University of Bern, Switzerland. PBL tutorial (32 lessons; 16 3 rd -year medical students). 5. Neurologie und Endokrinologie - Pathophysiologie, Summersemester University of Bern, Switzerland. PBL tutorial (40 lessons; 16 3 rd -year medical students). 6. Klinische Epidemiologie. Wintersemester 2006/07 and 2008/09. University of Bern, Switzerland. Lecture on systematic reviews and meta-analyses (2 lessons; approximately 40 3 rd /4 th -year dental medicine students). 7. Seminar Klinische Pharmazie. Wintersemester 2005/06. University of Bonn, Germany. Lecture and practical on evidence-based medicine (4 lessons; approximately 50 4th-year pharmacy students). Oral examination of undergraduate students 1. Medizinisch-Praktische Prüfung (MPP). Summersemester University of Bern, Switzerland. Co-examiner in medical statistics (50 1 st -year medical students). 2. Medizinisch-Praktische Prüfung (MPP). Summersemester University of Bern, Switzerland. Co-examiner in clinical epidemiology (50 1 st -year medical students). Co-Supervision of higher degree students 1. Nüesch E. Bias and variation in meta-analyses of randomized trials (PhD thesis). University of Bern, Switzerland. Approved. 2. Blank S. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis (MD thesis). Approved. Postgraduate teaching 1. Clinical Investigators II: advanced GCP & clinical research training course. One to two courses per year since CTU Bern, University of Bern, Switzerland. Practical on developing March

12 research objectives, lecture on clinical events and safety issues in clinical studies (3 lessons; approximately 20 clinical investigators). 2. Clinical research investigators I: basic training course. Two to four courses per year since CTU Bern, University of Bern, Switzerland. Lectures and practicals on study protocol, patient information/consent and safety issues in clinical studies (4 lessons; approximately 27 clinical investigators). 3. Einführung in systematische Reviews und Meta-Analysen. Every Summersemester 2008 to Institute of Social and Preventive Medicine, University of Bern, Switzerland. Lecture and practical on identifying relevant literature for systematic reviews (3 lessons; 24 MPH students). 4. Advanced methods in epidemiology: meta-analysis and systematic reviews. Every Wintersemester 2006/07 to 2008/09. Institute of Social and Preventive Medicine, University of Bern, Switzerland. Lectures on literature search, data extraction, and statistical methods of meta-analyses; computer practicals (15 lessons; 24 MPH students) 5. Advanced methods in epidemiology: applied regression modelling. Wintersemester 2006/07. Institute of Social and Preventive Medicine. Computer practical on linear regression (2 lessons; 24 MPH students) Supervision of postgraduate degree students 1. Sterchi R. Transparenz in der Berichterstattung von randomisierten, kontrollierten Studien und Studienqualität in der Arthrose-Forschung Eine Zeittrendanalyse über 30 Jahre (MPH thesis). University of Bern, Switzerland. Approved. Further education 1. Lehr- und Fachvorträge. University of Bern, Switzerland. Workshop on various aspects of lectures and presentations: Sep 12 & 21, PBL-Tutorenausbildung. University of Bern, Switzerland. Course for problem-based learning tutors: Jan 25-26, Basics der Hochschuldidaktik. University of Bern, Switzerland. Workshop on didactics: Oct 15-17, Produktion von Multiple Choice Fragen für das Staatsexamen. University of Bern, Switzerland. Workshop on developing multiple choice questions: Feb 27, March

13 Grants 1. A structured early palliative care intervention for patients with advanced cancer a randomized controlled trial with a nested qualitative study. Swiss National Science Foundation CHF 331,323 Co-applicant. 2. Optimizing treatment strategies for patients with osteoarthritis. ARCO Foundation, Switzerland CHF 1,490,000. Co-applicant. 3. Individual patient data meta-analysis on the effects of erythropoiesis-stimulating agents in cancer patients. Oncosuisse, Switzerland CHF 140,971. Co-applicant. 4. Meta-Base: Developing a data management software for systematic reviews and meta-analyses. Swiss National Science Foundation CHF 144,142. Main applicant. 5. Enhancing and updating the osteoarthritis module of The Cochrane Library. Swiss National Science Foundation CHF 140,614. Co-applicant. 6. Clinical Trial Unit Bern. Swiss National Science Foundation CHF 1,051,358. Member of the writing committee. 7. Femoro-acetabular impingement: role in osteoarthritis of the hip. Swiss National Science Foundation CHF 50,460. Co-applicant. 8. Familial aggregation of femoro-acetabular impingement: a pilot study. Swiss National Science Foundation CHF 99,125. Co-applicant. 9. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data. Federal Ministry of Education and Research Euro 73,404. Co-applicant. Schmitten, 3/7/2013 Sven Trelle March

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black

More information

Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update

Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update Comparative Effectiveness Review Number 113 Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update Comparative Effectiveness Review Number

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

QUADAS-2: Background Document

QUADAS-2: Background Document QUADAS-2: Background Document QUADAS-2 QUADAS-2 is designed to assess the quality of primary diagnostic accuracy studies; it is not designed to replace the data extraction process of the review and should

More information

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1 COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize

More information

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and

More information

Health Benchmarks Program Clinical Quality Indicator Specification 2013

Health Benchmarks Program Clinical Quality Indicator Specification 2013 Health Benchmarks Program Clinical Quality Indicator Specification 2013 Measure Title USE OF IMAGING STUDIES FOR LOW BACK PAIN Disease State Musculoskeletal Indicator Classification Utilization Strength

More information

Guidelines for the Management of Follicular Lymphoma

Guidelines for the Management of Follicular Lymphoma Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World

More information

Master Online Study Program @dvanced Oncology. Study part time team up internationally!

Master Online Study Program @dvanced Oncology. Study part time team up internationally! Master Online Study Program @dvanced Oncology Study part time team up internationally! Ulm University is developing an innovative international postgraduate study program @dvanced Oncology addressing clinical

More information

Lymphoma: The Roleof Nurses in the Treatment Process

Lymphoma: The Roleof Nurses in the Treatment Process Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Claudia M. Witt, MD, MBA

Claudia M. Witt, MD, MBA Costs and cost-effectiveness of Complementary and Alternative Medicine Complementary and Alternative Medicine Innovation and Added Value for European Healthcare 9 October 2012 European Parliament, Brussels

More information

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health Introduction Reader (Statistics and Epidemiology) Research team epidemiologists/statisticians/phd students Primary care

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

Molecular markers and clinical trial design parallels between oncology and rare diseases?

Molecular markers and clinical trial design parallels between oncology and rare diseases? Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

Plan of the Session. Session I: Basic Methods of Meta-Analysis Short Introduction to R. Why Conduct a Meta-Analysis? What is a Meta-Analysis?

Plan of the Session. Session I: Basic Methods of Meta-Analysis Short Introduction to R. Why Conduct a Meta-Analysis? What is a Meta-Analysis? Session I: Basic Methods of Meta-Analysis Short Introduction to R James Carpenter 1, Ulrike Krahn 2,3, Gerta Rücker 4, Guido Schwarzer 4 1 London School of Hygiene and Tropical Medicine & MRC Clinical

More information

In the last decade, passive immunotherapy

In the last decade, passive immunotherapy Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,

More information

Formulating the Review Question & Writing a Protocol

Formulating the Review Question & Writing a Protocol Formulating the Review Question & Writing a Protocol Madhukar Pai, MD, PhD Associate Professor Department of Epidemiology & Biostatistics McGill University, Montreal, Canada Email: madhukar.pai@mcgill.ca

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06

More information

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Not All Clinical Trials Are Created Equal Understanding the Different Phases Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact

More information

David Loew, LCL MabThera

David Loew, LCL MabThera MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

Anti-HCV therapy in HCV-related NHL

Anti-HCV therapy in HCV-related NHL Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

Interesting Case Series. Periorbital Richter Syndrome

Interesting Case Series. Periorbital Richter Syndrome Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,

More information

Guide to Biostatistics

Guide to Biostatistics MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading

More information

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated

More information

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr Stefan Pilz Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Austria Department

More information

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth

More information

Irish Haemophilia Society. Introduction to Haemophilia. Brian O Mahony November 2009

Irish Haemophilia Society. Introduction to Haemophilia. Brian O Mahony November 2009 Irish Haemophilia Society Introduction to Haemophilia Brian O Mahony November 2009 1 Content Introduction to Haemophilia Introduction to Von Willebrand's Disease Inheritance Bleeding patterns Introduction

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone:

More information

Measure Title X RAY PRIOR TO MRI OR CAT SCAN IN THE EVAULATION OF LOWER BACK PAIN Disease State Back pain Indicator Classification Utilization

Measure Title X RAY PRIOR TO MRI OR CAT SCAN IN THE EVAULATION OF LOWER BACK PAIN Disease State Back pain Indicator Classification Utilization Client HMSA: PQSR 2009 Measure Title X RAY PRIOR TO MRI OR CAT SCAN IN THE EVAULATION OF LOWER BACK PAIN Disease State Back pain Indicator Classification Utilization Strength of Recommendation Organizations

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

Quality and Clinical Director

Quality and Clinical Director Curriculum Vitae PERSONAL INFORMATION Minna Leppänen WORK EXPERIENCE April 2014 Present Quality and Clinical Director Scaffdex Ltd, (Finland) Responsibility in quality, regulatory and clinical issues concerning

More information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University

More information

A pilot study of the primary care management of knee osteoarthritis in the Northern States of Malaysia.

A pilot study of the primary care management of knee osteoarthritis in the Northern States of Malaysia. A pilot study of the primary care management of knee osteoarthritis in the Northern States of Malaysia. Arshad A and Rashid R Putra Specialist Centre, Alor Setar, Kedah, Malaysia ABSTRACT ORIGINAL ARTICLE

More information

REGULATIONS FOR THE POSTGRADUATE CERTIFICATE IN PUBLIC HEALTH (PCPH) (Subject to approval)

REGULATIONS FOR THE POSTGRADUATE CERTIFICATE IN PUBLIC HEALTH (PCPH) (Subject to approval) 512 REGULATIONS FOR THE POSTGRADUATE CERTIFICATE IN PUBLIC HEALTH (PCPH) (Subject to approval) (See also General Regulations) M.113 Admission requirements To be eligible for admission to the programme

More information

Practice of Interferon Therapy

Practice of Interferon Therapy Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department

More information

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008 Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

This is the author s version of a work that was submitted/accepted for publication in the following source:

This is the author s version of a work that was submitted/accepted for publication in the following source: This is the author s version of a work that was submitted/accepted for publication in the following source: Chan, Raymond Javan, Phillips, Jane, & Currow, David (2014) Do palliative care health professionals

More information

Publication Bias in medical research: issues and communities

Publication Bias in medical research: issues and communities Publication Bias in medical research: issues and communities Edgar Schiebel and Maria Elisabeth Züger edgar.schiebel@ait.ac.at, maria-elisabeth.zueger@ait.ac.at AIT Austrian Institute of Technology GmbH,

More information

Master of Public Health (MPH) SC 542

Master of Public Health (MPH) SC 542 Master of Public Health (MPH) SC 542 1. Objectives This proposed Master of Public Health (MPH) programme aims to provide an in depth knowledge of public health. It is designed for students who intend to

More information

Dietary treatment of cachexia challenges of nutritional research in cancer patients

Dietary treatment of cachexia challenges of nutritional research in cancer patients Dietary treatment of cachexia challenges of nutritional research in cancer patients Trude R. Balstad 4th International Seminar of the PRC and EAPC RN, Amsterdam 2014 Outline Cancer cachexia Dietary treatment

More information

Follicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.

Follicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org. Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk is a cancer of the lymphatic system, a type of non-hodgkin lymphoma. Even though more than 12,000 people are diagnosed

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular

More information

Overview: 1. Epidemiology of childhood cancer survivorship 2. Late effects 3. Palliative care of survivors 4. Examples

Overview: 1. Epidemiology of childhood cancer survivorship 2. Late effects 3. Palliative care of survivors 4. Examples Childhood Cancer Survivorship Jacqueline Casillas, M.D., M.S.H.S. Associate Program Director of the UCLA-LIVESTRONG LIVESTRONGTM TM Center of Excellence for Survivorship Care Overview: 1. Epidemiology

More information

An overview of current CLL clinical trials in Europe

An overview of current CLL clinical trials in Europe An overview of current CLL clinical trials in Europe CENTER/GROUP TRIAL SITUATION CONTACT PERSONS OTHER REMARKS INFORMATION LAST Europewide Nordic-Dutch-Polish- Czech-Israeli Czech Republic Czech Leukemia

More information

Neue Aspekte der Gerinnung: von neuen Antikoagulantien bis zur Trauma-induzierten Koagulopathie

Neue Aspekte der Gerinnung: von neuen Antikoagulantien bis zur Trauma-induzierten Koagulopathie 3. Fortbildungstag des forum Klinische Notfallmedizin SGNOR und der SIN Bern, 31.10.2012 Neue Aspekte der Gerinnung: von neuen Antikoagulantien bis zur Trauma-induzierten Koagulopathie Lorenzo ALBERIO

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

ISPI Newsletter Archive - Whiplash

ISPI Newsletter Archive - Whiplash ISPI Newsletter Archive - Whiplash March 2005 Widespread Sensory Hypersensitivity Is a Feature of Chronic Whiplash - Associated Disorder but not Chronic Idiopathic Neck Pain. Clin J Pain. 2005 Mar-Apr;21

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA 2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate

More information

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo * This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Journal Presentation

More information

TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness

TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness DATE: 09 October 2008 RESEARCH QUESTION: What is the clinical effectiveness of auricular acupuncture in the management

More information

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory

More information

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.

More information

CHRONIC LYMPHOCYTIC LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA Executive Summary Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world, but is significantly less frequent in Asia. The median age of

More information

David Feltl, M.D., Ph.D., MBA. Structure and organization of cancer care in the Czech Republic. Assessment of outputs and outcomes.

David Feltl, M.D., Ph.D., MBA. Structure and organization of cancer care in the Czech Republic. Assessment of outputs and outcomes. David Feltl, M.D., Ph.D., MBA Structure and organization of cancer care in the Czech Republic. Assessment of outputs and outcomes. Contents Cancer epidemiology in the Czech Republic National oncology program

More information

Cure versus control: Which is the best strategy?

Cure versus control: Which is the best strategy? Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control

More information

Comment Form: WHO Statement on Public Disclosure of Clinical Trial Results. Suggested Amendment

Comment Form: WHO Statement on Public Disclosure of Clinical Trial Results. Suggested Amendment Form: WHO Statement on Public Disclosure of Clinical Trial Results Page 1 of 6 as individual or on behalf of agency or institution?: Institution er's Name in Full, Title, Institution, City, Country, Tel.,

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection

More information

Monash University - Master of Clinical Pharmacy

Monash University - Master of Clinical Pharmacy Monash University - Master of Clinical The Master of Clinical is a 48 credit point program, equivalent to one year of full time study (generally completed in 2 years part time). It comprises 1200 hours

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Depression in patients with coronary heart disease (CHD): screening, referral and treatment. 2014 Na)onal Heart Founda)on of Australia

Depression in patients with coronary heart disease (CHD): screening, referral and treatment. 2014 Na)onal Heart Founda)on of Australia Depression in patients with coronary heart disease (CHD): screening, referral and treatment Screening, referral and treatment for depression in patients with CHD A consensus statement from the National

More information

MorphoSys Proprietary Development Update

MorphoSys Proprietary Development Update September 8, 2015 MorphoSys Proprietary Development Update 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of highdose chemotherapy for breast cancer patients Marino P, Siani C, Roche H, Moatti J P Record Status This is a critical

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

COMPENDIA TRANSPARENCY TRACKING FORM. Sunitinib malate. Metastatic breast cancer, HER2-negative

COMPENDIA TRANSPARENCY TRACKING FORM. Sunitinib malate. Metastatic breast cancer, HER2-negative COMPENDIA TRANPARENCY TRACKING FORM DRUG: unitinib malate INDICATION: Metastatic breast cancer, HER2-negative COMPENDIA TRANPARENCY REQUIREMENT 1 Provide criteria used to evaluate/prioritize the request

More information

Department of Behavioral Sciences and Health Education

Department of Behavioral Sciences and Health Education ROLLINS SCHOOL OF PUBLIC HEALTH OF EMORY UNIVERSITY Core Competencies Upon graduation, a student with an MPH/MSPH should be able to: Use analytic reasoning and quantitative methods to address questions

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development

More information

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly

More information

New Targets and Treatments for Follicular Lymphoma. Disclosures

New Targets and Treatments for Follicular Lymphoma. Disclosures Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:

More information

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology)

REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology) 463 REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology) (See also General Regulations) M.57 Admission requirements To be eligible for admission to the courses

More information

REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology)

REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology) 452 REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology) (See also General Regulations) M.57 Admission requirements To be eligible for admission to the courses

More information

The Swiss National Clinical Trials Portal a new database on clinical trials?

The Swiss National Clinical Trials Portal a new database on clinical trials? The Swiss National Clinical Trials Portal a new database on clinical trials? Meet and Greet for Swiss Biomedical Librarians 8 September 2014, Hotel Kreuz, Berne Hosted by the Biomedical Library Committee

More information

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:

More information

Evaluation of the methodology in publications describing epidemiological design for dental research: a critical analysis

Evaluation of the methodology in publications describing epidemiological design for dental research: a critical analysis ISSN: Versão impressa: 1806-7727 Versão eletrônica: 1984-5685 RSBO. 2011 Jan-Mar;8(1):75-80 Original Research Article Evaluation of the methodology in publications describing epidemiological design for

More information

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引 前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

More information

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources

Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources James Floyd, MD, MS Sep 17, 2015 UW Hospital Medicine Faculty Development Program Objectives Become more

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

Reporting guidelines: past, present and future

Reporting guidelines: past, present and future Reporting guidelines: past, present and future Acknowledge: Doug Altman, Isabelle Boutron, John Hoey, Sally Hopewell, Philippe Ravaud, Drummond Rennie, Ken Schulz, and Iveta Simera Health research reporting

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

Evaluation of training of authors of Cochrane systematic reviews in New Zealand and a pilot of a web-based alternative

Evaluation of training of authors of Cochrane systematic reviews in New Zealand and a pilot of a web-based alternative Evaluation of training of authors of Cochrane systematic reviews in New Zealand and a pilot of a web-based alternative Jane Clarke Centre for Medical and Health Sciences Education Faculty Medical and Health

More information